Abstract 154P
Background
This retrospective multicenter real-world study aims to investigate the potential prognostic value of AEs in HCC patients treated with AB in first-line setting.
Methods
The study’s population consisted of 823 HCC patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea) treated with AB between October 2018 and April 2022.
Results
Median overall survival (OS) was 15.9 months and median progression-free survival (PFS) was 7.6 months. 73.3% of patients presented at least one AE during the study period. The most common AEs were proteinuria (29.6%), arterial hypertension (27.2%), and fatigue (26.0%). 17.3% of the AEs were grade (G) 3. One death due to bleeding was reported. The multivariate analysis confirmed the appearance of decreased appetite G < 2 versus G ≥ 2 [hazard ratio (HR): 0.60; p < 0.01] and immunotoxicity G < 2 versus G ≥ 2 (HR: 0.70; p = 0.04) as independent prognostic factors for OS, and the appearance of decreased appetite G < 2 versus G ≥ 2 (HR: 0.73; p = 0.01), diarrhea of any G versus no diarrhea (HR: 0.57; p = 0.01), fatigue of any G versus no fatigue (HR: 0.82; p < 0.01), arterial hypertension G < 2 versus G ≥ 2 (HR: 0.68; p < 0.01), and proteinuria of any G versus no proteinuria (HR: 0.79; p = 0.03) as independent prognostic factors for PFS. The objective response rate (ORR) was 27.3%: complete responses (CR) were 35 (4.2%), partial response 190 (23.1%), stable disease 428 (52.0%), and progressive disease 170 (20.7%). The appearance of hypothyroidism of any G (odds ratio: 0.52; p = 0.04) and immunotoxicity of any G (odds ratio: 0.54; p < 0.01) were correlated with higher ORR, while the absence of fatigue of any G (odds ratio: 3.90; p = 0.02) and decreased appetite of any G (odds ratio: 9.71; p = 0.02) were correlated with more CR.
Conclusions
As also demonstrated for other therapies, also for the combination of AB there is a correlation between the occurrence of AEs and HCC patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract